UR-3216: A New Generation Oral Platelet GPIIb / IIIa Antagonist

E-ISSN： 1873-4286|10|14|1597-1601

ISSN： 1381-6128

Source： Current Pharmaceutical Design, Vol.10, Iss.14, 2004-05, pp. : 1597-1601

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Targeting the Platelet Integrin GPIIb/IIIa

Current Pharmaceutical Design, Vol. 16, Iss. 37, 2010-12 ,pp. : 4119-4133

Bentham Science Publishers

Access to resources Recommend Favorite

Antiplatelet Therapies: Platelet GPIIb / IIIa Antagonists and Beyond

Current Pharmaceutical Design, Vol. 9, Iss. 28, 2003-11 ,pp. : 2317-2322

Bentham Science Publishers

Access to resources Recommend Favorite

Superiority of platelet integrin GPIIb-IIIa receptor antagonist over aspirin in preventing cyclic flow reductions in the guinea pig middle cerebral artery

By Kawano K.-i. Ikeda Y. Kondo K. Umemura K.

European Journal of Pharmacology, Vol. 374, Iss. 3, 1999-06 ,pp. : 377-385

Elsevier

Access to resources Recommend Favorite

Oral GPIIb / IIIa Antagonists: What Went Wrong?

Current Pharmaceutical Design, Vol. 10, Iss. 14, 2004-05 ,pp. : 1587-1596

Bentham Science Publishers

Access to resources Recommend Favorite

Lotrafiban: an oral platelet glycoprotein IIb/IIIa blocker

By Liu F. Craft R.M. Morris S.A. Carroll R.C.

Expert Opinion on Investigational Drugs, Vol. 9, Iss. 11, 2000-11 ,pp. : 2673-2687

Informa Healthcare

Access to resources Recommend Favorite